- Trials with a EudraCT protocol (10,988)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10,988 result(s) found.
Displaying page 252 of 550.
EudraCT Number: 2012-000802-32 | Sponsor Protocol Number: CLCQ908B2305 | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open label, long-term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021375-92 | Sponsor Protocol Number: 1276.1 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual c... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005559-46 | Sponsor Protocol Number: 205MS202 | Start Date*: 2009-01-23 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022757-42 | Sponsor Protocol Number: IMM-101-002 | Start Date*: 2011-05-17 | |||||||||||
Sponsor Name:Immodulon Therapeutics Limited | |||||||||||||
Full Title: A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Advanced pancreatic cancer The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and to... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002400-40 | Sponsor Protocol Number: CTTG01-01 | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:Targovax AS | |||||||||||||
Full Title: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas | |||||||||||||
Medical condition: Adenocarcinoma of the Pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) GB (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002665-38 | Sponsor Protocol Number: M/34273/40 | Start Date*: 2011-10-05 | |||||||||||
Sponsor Name:Almirall S.A. | |||||||||||||
Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2 PERIOD CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 μg BID ON EXERCISE ENDURANCE IN PATIENTS WITH STABLE ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005686-12 | Sponsor Protocol Number: RD.03.SPR.29107 | Start Date*: 2013-05-23 | |||||||||||
Sponsor Name:Galderma R&D | |||||||||||||
Full Title: Patient-reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea | |||||||||||||
Medical condition: Erythema of rosacea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004942-14 | Sponsor Protocol Number: CLDT600A2306 | Start Date*: 2014-05-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, 104-weeks treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of telbivudine oral solution and tablets in children and adolescents with c... | |||||||||||||
Medical condition: compensated HBeAg-positive and negative chronic hepatitis B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) GR (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001067-79 | Sponsor Protocol Number: ColoAd1-1001 | Start Date*: 2012-08-21 | |||||||||||
Sponsor Name:Psioxus Therapeutics Ltd. | |||||||||||||
Full Title: A Phase I / II Dose Escalation and Randomised Controlled Trial of ColoAd1 Administered by Sub-acute Fractionated Intravenous Injection to Patients with Metastatic Colorectal Cancer | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004567-21 | Sponsor Protocol Number: 3119001 | Start Date*: 2015-06-05 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001103-23 | Sponsor Protocol Number: PA0008 | Start Date*: 2016-11-21 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS | |||||||||||||
Medical condition: psoriatic arthritic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003661-26 | Sponsor Protocol Number: HX-02-PEP | Start Date*: 2017-02-16 | |||||||||||
Sponsor Name:Haemostatix Ltd | |||||||||||||
Full Title: A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStat in intraoperative surgical haemostasis | |||||||||||||
Medical condition: To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or sutures; or are inappropriate. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001154-14 | Sponsor Protocol Number: Vonoprazan-2001 | Start Date*: 2016-05-23 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatm... | |||||||||||||
Medical condition: Gastro-Esophageal Reflux Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) EE (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003099-30 | Sponsor Protocol Number: CAIN457X2201 | Start Date*: 2017-11-02 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group, Phase II, 24-week study investigating the efficacy, safety and tolerability of AIN457 in patients with active overuse tendinopathy re... | |||||||||||||
Medical condition: Overuse rotator cuff tendinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002603-29 | Sponsor Protocol Number: ALN-TTRSC-005 | Start Date*: 2015-12-01 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc | |||||||||||||
Full Title: An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Trans... | |||||||||||||
Medical condition: Transthyretin (TTR)-mediated Familial Amyloidotic Polyneuropathy (FAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) PT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001489-85 | Sponsor Protocol Number: FRM-0334-002 | Start Date*: 2015-02-23 | |||||||||||
Sponsor Name:FORUM Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects wit... | |||||||||||||
Medical condition: Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002530-50 | Sponsor Protocol Number: EspeRare_RIM_001 | Start Date*: 2015-11-04 | |||||||||||
Sponsor Name:EspeRare | |||||||||||||
Full Title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001063-12 | Sponsor Protocol Number: EVB-003 | Start Date*: 2015-04-22 | |||||||||||
Sponsor Name:Evolus Inc. | |||||||||||||
Full Title: A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-s... | |||||||||||||
Medical condition: moderate-to-severe glabellar lines | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002919-15 | Sponsor Protocol Number: CLS001-CO-PR-004 | Start Date*: 2015-11-16 | |||||||||||
Sponsor Name:Cutanea Life Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subject... | |||||||||||||
Medical condition: Papulopustular rosacea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Ongoing) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002698-39 | Sponsor Protocol Number: CB8025-21528 | Start Date*: 2015-11-11 | |||||||||||
Sponsor Name:CymaBay Therapeutics Inc. | |||||||||||||
Full Title: A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response t... | |||||||||||||
Medical condition: Primary Biliary Cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
